Podcast appearances and mentions of jeffrey dunn

In this episode of Set Lusting Bruce, host Jesse Jackson steps away from Bruce Springsteen discussions to delve into the fascinating world of bourbon and writing with guest Jeffrey Dunn. Jeffrey speaks about his new book 'Whiskey Rebel' and shares his journey as an author, his inspirations from different geographies, and his teaching career. The episode also touches on Bruce Springsteen's influence on Jeffrey's writing and includes a spirited discussion on the American Dream and working-class struggles. Tune in for a deep conversation that intertwines literature, history, and music. https://jeffreydunnspokane.com/ 00:00 Introduction to Set Lusting Bruce 01:17 Guest Introduction: Jeffrey Dunn 01:29 Jeffrey's Background and Writing Journey 03:24 The Inspiration Behind Whiskey Rebel 07:48 Jeffrey's Reading and Music Influences 15:30 Bruce Springsteen's Influence on Whiskey Rebel 20:44 The Magic of Storytelling 22:15 A Personal Journey Through Writing 24:06 Teaching with Music and Poetry 26:57 Exploring Different Writing Genres 30:24 The Mary Question 37:27 Final Thoughts and Farewell Learn more about your ad choices. Visit megaphone.fm/adchoices

Radio Free OlympiaUnleash the Power of the Wilderness in Radio Free OlympiaDiscover the captivating allure of Washington's untamed Olympic Peninsula in Radio Free Olympia, an extraordinary literary masterpiece that immerses readers in a mesmerizing realm of visionaries, folklore legends, and historical icons. With an enchanting blend of magical realism and cultural fiction, the brilliant wordsmith Jeffrey Dunn artfully intertwines multiple narratives, crafting an intricate ecological tapestry that resonates deeply within the soul.Embark on a riveting journey alongside the enigmatic Petr, a foundling whose path leads him deep into the heart of the majestic mountain rainforest. Armed with nothing but a pirate radio transmitter, Petr fearlessly broadcasts the forgotten and untamed voices that echo through the wilderness. As you venture deeper into this mystical world, you will encounter Baie, a resilient woman who establishes Wildsisters, an inviting haven infused with the essence of cranberries, offering solace to the lost and wayward souls who cross her path.However, when an innocent newborn is cruelly snatched from the sanctuary of Wildsisters, Baie and her community of resilient women must unite and summon the strength to recover what has been stolen. Yet, the quest for justice extends far beyond the realm of human characters. In this awe-inspiring tale, justice must also be served for the fragile flora, the diverse fauna, and the very essence of the rugged terrain that forms the backdrop of this extraordinary narrative.Radiating with eloquent prose and evocative poetry, Radio Free Olympia flawlessly merges fiction and history, seamlessly blending the gritty allure of hard-boiled storytelling with the ethereal realms of the transcendent. Dunn masterfully harmonizes these contrasting elements, inviting readers to connect with the spiritual essence of this extraordinary place.Prepare to be utterly spellbound as Radio Free Olympia beckons you to immerse yourself in the vivid tapestry of a land that transcends conventional boundaries. With its poetic grace, unyielding prose, and a cast of unforgettable characters, this profound masterpiece invites you to explore the deeper recesses of your own soul and uncover the profound interconnectedness between humanity and the natural world. Hosted on Acast. See acast.com/privacy for more information.

Today's episode includes a discussion with Dr. Jeffrey Dunn who serves as the Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology within the Department of Neurology & Neurological Sciences at Stanford University. The discussion includes an overview of the different types of stem cells, as it relates to Multiple Sclerosis (MS), some of the ways researchers are considering using stem cell therapy to treat MS, and the limitations of disease modifying treatments that stem cell therapy could help address. Advice will also be provided to clinicians whose patients are asking about stem cell therapy and when it will be available to them. This session focuses on the knowledge gaps around the risks and benefits of stem cell therapy and the ongoing research taking place to bring this therapeutic option from bench to bedside. Read Transcript CME Information: https://stanford.cloud-cme.com/medcastepisode43 Claim CE: https://stanford.cloud-cme.com/Form.aspx?FormID=1220 This CME Activity is supported by an educational grant from Novartis Pharmaceuticals Corporation. 

In this podcast, we hear from Jeffrey Dunn the President, CEO & Chairman of SI-BONE, Inc. Here he discusses how surgeons are moving to have more SI fusion procedures in ASCs, what happened when covid hit in mid-march and how things are going now. This episode is sponsored by SI-BONE.

In this podcast, we hear from Jeffrey Dunn the President, CEO & Chairman of SI-BONE, Inc. Here he discusses how surgeons are moving to have more SI fusion procedures in ASCs, what happened when covid hit in mid-march and how things are going now.  This episode is sponsored by SI-BONE. (https://si-bone.com/)

Jessie Jeffrey Dunn Rovinelli is a filmmaker. She recently wrote, directed and starred in a feature titled "So Pretty," which is, according to Jessie, "a narrative-ish film following four to six young gender deviants in New York City as they nap and fuck and try to get by as best they can." The film is an adaptation, and translation, of a novel by gay German writer Ronald M. Schernikau, which originally was set in 1980s West Berlin. The worlds of queer housing and rave scenes overlap with mass protest in "So Pretty," as staged and real settings blend. In this interview, which took place in Jessie's bedroom in Brooklyn, we discuss becoming an optimist through art, Donald Trump's effect on mobilization, transitioning while making a film, the community built when making a film, and the importance of Black Lives Matter, J20, and Occupy Wall Street. More information on upcoming screenings of "So Pretty" can be found here. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/protest-and-survive/support

On the evening of Thursday, May 03rd, 1877, two men were hanged from the Water Street bridge in Santa Cruz California. Were there racist tensions that led to this episode of mob justice? Were these men denied justice by not getting their day in court? Case historians Jeffrey Dunn and Casey Tefertiller discuss the disturbing details of one of the darkest days in Santa Cruz history.

Over the weekend, I attended the MS Breakthroughs event put on by the National MS Society. The keynote speaker was Jeffrey Dunn, director of the Stanford MS Center. The event promised to inform about the current-day MS Breakthroughs as well as the future of MS Research.

Indie Beat - Jessie Jeffrey Dunn Rovinelli by The Playlist --- Send in a voice message: https://anchor.fm/theplaylist/message

14 May 2013: In this podcast, Dr. Jeffrey Dunn speaks with Dr. Jared Jagdeo about the effects of light emitting diode (LED) low level light therapy (LLLT) on human skin.

16 May 2013: In this podcast, Dr. Jeffrey Dunn speaks with Dr. Jared Jagdeo about how immunohistochemical staining patterns aid in our understanding of the role of oxidative damage in photoaging.

21 May 2013: In this podcast, Dr. Jeffrey Dunn speaks with Emilee Sandsmark and Monica Salazar about the potential for tattoo websites to promote overall long-term sun safety for skin cancer prevention.

04 January 2013: Join presenter Dr. Jeffrey Dunn as he speaks with Dr. Ruby Ghadially about the past 25 years of epidermal stem cell research. Understanding of epidermal stem cell biology has evolved rapidly as techniques to visualize distribution of stem cells and progeny have improved. However, significant challenges remain, including defining molecular markers for stem cells, determining the locations and contributions of different stem cell niches, and mapping regulatory pathways of epidermal stem cell proliferation and differentiation.

New electro-acoustic music by influential experimental composer Warren Burt and five of his recent students.

New electro-acoustic music by influential experimental composer Warren Burt and five of his recent students.

In this episode, Jeremy Thake talks to Dean Slawson and Jeffrey Dunn on best practices for Office add-ins.   Weekly updates Use OAuth authentication in an Office add-in Microsoft Graph: Outlook Extensions by Simon Jaeger Announcing Fabric Explorer by David Mann Microsoft Graph in Ruby on Rails app (Office Dev Show) by Richard diZerega Show notes Office add-in development best practices Office add-in training Got questions or comments about the show? Join the O365 Dev Podcast on the Office 365 Technical Network. The podcast RSS is available iTunes or search for it on “Office 365 Developer Podcast” or add directly with the RSS http://feeds.feedburner.com/Office365DeveloperPodcast. About the hosts Jeremy is a technical product manager at Microsoft responsible for the Visual Studio Developer story for Office 365 development. Previously he worked at AvePoint Inc., a large ISV, as the chief architect shipping two apps to the Office Store. He has been heavily involved in the SharePoint community since 2006 and was awarded the SharePoint MVP award four years in a row before retiring the title to move to Microsoft. You can find Jeremy blogging at www.jeremythake.com and tweeting at @jthake.   Richard is a software engineer in Microsoft’s Developer Experience (DX) group, where he helps developers and software vendors maximize their use of Microsoft cloud services in Office 365 and Azure. Richard has spent a good portion of the last decade architecting Office-centric solutions, many that span Microsoft’s diverse technology portfolio. He is a passionate technology evangelist and frequent speaker are worldwide conferences, trainings and events. Richard is highly active in the Office 365 community, popular blogger at www.richdizz.com and can be found on Twitter at @richdizz. Richard is born, raised and based in Dallas, TX, but works on a worldwide team based in Redmond. Richard is an avid builder of things (BoT), musician and lightning-fast runner

[intro music]   Host – Dan Keller Hello, and welcome to Episode Six of Multiple Sclerosis Discovery, the Podcast of the MS Discovery Forum. I’m your host, Dan Keller.   This week’s Podcast features an interview with Dr. Jeffrey Dunn, who explores the prospect of personalized medicine in MS. But to begin, here’s a brief summary of some of the topics we’ve been covering on the MS Discovery Forum at msdiscovery.org.   Recently, blogger Emily Willingham shared a person experience with MRI interpretation in our blog, MS Patient, Ph.D. She wrote, “I’ve come to realize in my various dealings with MRI reports that neuroradiologists are like economists; everyone has an opinion and no two readers will agree on what they see in exactly the same data.” Willingham, a developmental biologist, provides a unique view into the life of an MS patient. Her experiences bring a first-person perspective of MS, while her scientific background informs her insights in a way that many researchers and clinicians may find valuable.   We’d also like to bring your attention to the data visualization section of the MSDF website. Under the research resources tab, you can find a series of interactive data visualizations useful for MS researchers. One visualization aggregates 106 clinical trials. You can organize the data by the compound, phase, population, or even the funding. Our latest visualization is of the natural history of MS symptoms. The interactive bar chart allows you to see the change of various symptom severity in MS over a 30-year period.   Also in research resources, check out the drug development pipeline. This is where we keep detailed information on, at last count, 40 drugs currently in development or on the market for MS. This database, which is updated daily as new information becomes available, contains a wealth of data on each agent. This includes the agent’s class, its intended target and routes of administration, its regulatory status and commercial history, its chemical properties, mechanism of action and adverse effects, and all its clinical trials.   Now for the interview. Dr. Jeffrey Dunn is a Professor of Neurology and Neurological Sciences at Stanford University. He met with MSDF editor Bob Finn to discuss the use of biomarkers and personalized medicine. But first he shared a little history.   Interviewee – Jeffrey Dunn So, in the history of multiple sclerosis, when cases of CNS demyelinating disease were first discovered, they were discovered as isolated case instances at a number of different and variable institutions throughout Europe and in the United States. The doctors knew of the patients’ symptoms, of course, because they had cared for them. Many of these patients went on to pathology examination, and multiple cases of areas of inflammation or even scar formation were seen within the central nervous system. These cases from the mid-1800s and into the late-1800s were described as isolated instances. And the physician who is given credit for the discovery of what we now know to be multiple sclerosis was Dr. John-Martin Charcot in Paris, because he had had the experience of a very close relationship with a patient he named Mademoiselle V. He had known that she had had a tremor and ataxia and eye movement abnormalities, so Charcot knew his patient’s phenotype, her clinical manifestations, very well, and specifically had seen evidence of eye movement abnormalities, tremor, and ataxia. She had consented to have her nervous system evaluated pathologically, and so Charcot was able to make a connection between what she had looked like in life, and then what her brain and spinal cord had looked like after she had passed away.   It’s that clinicopathologic correlation that really was a paradigm-buster at the time. And Charcot found palpably hard spots – areas of gliosis or scar formation – that occurred in plaques and patches throughout the spinal cord and brain (and cerebellum in this case). He called the disease almost an adjective really; he called it “la sclérose en plaques”, which is French for sclerosis – meaning hard spots essentially – in plaques. So hard spots was the disease. Multiple sclerosis is really an adjective more than a diagnosis. But in the early 20th Century leading up to the mid-20th century, there was increasing recognition on the basis of these isolated case reports that this disease that was now increasingly being called multiple sclerosis might be far more common than people had realized, and great credit needs to be given to Sylvia Lawry, who as you know was the founder of the National Multiple Sclerosis Society. The National MS Society was put together to try to bring physicians together to create a forum by which they could crosstalk, share the anecdotal information each of them had compiled, and come up with a more systematic review so that the disease could be better described and so that treatments could be more likely discovered. This was a huge step forward in terms of our discovery and ability to diagnosis and ultimately later to treat MS, but it created a framework that said that MS was, in some respects, one disease.   Now all of us even today, I would say, as physicians are trained that MS is a distinct disease; that it’s one type of disease with many variations according to individuals, but I think we’re actually at the very beginning of a very important paradigm shift in this consideration. There’s a difference, of course, between a disease and a syndrome. A disease is a quantifiable isolated entity – a classic example might be a genetic disorder caused by a single mutation in a coding sequence of DNA – whereas a syndrome is probably a collection of different but closely related diseases. I think there’s increasing evidence now, an increasing recognition that MS may be very heterogeneous and variable across individuals; I don’t think there would be any argument among my colleagues that MS is a heterogeneous process. My suggestion to you is that now, I think, we’re at the threshold of a paradigm that says that MS should not be regarded as a monolith or a single pathologic entity, but maybe more as a Stonehenge; a collection of closely related conditions that share some common pathology, but that need to be considered on an individual basis.   At the clinical, radiologic, immunologic, and pathologic levels we have evidence that MS is very heterogeneous among individuals. I think the theory that we now need to proceed according to is that multiple sclerosis is not one disease entity, but a number of different conditions. This idea and paradigm of personalized medicine is gaining traction. Our oncology colleagues who treat cancer have used this with some great and promising success in terms of applying optimum regimens and chemotherapeutic protocols to their patients, but I think there’s tremendous opportunity in multiple sclerosis to practice personalized medicine, because I think that the process of MS is a personalized one in which there are unique and eminently measurable proteins or protein profiles one day we’ll be able to identify, and hopefully that day is soon, and we can use that as the rationale for our prescription for the patients.   Interviewer – Bob Finn So when some people think about biomarkers, they think about an individual protein or some other biological signal that will be prognostic or in some other way tell you about what the patient is experiencing or might experience. It sounds to me like you’re talking about not an individual biomarker, but a constellation of biomarkers that would provide a fingerprint. Am I right about that?   Dr. Dunn I think so. Just as the disease pathogenesis itself is heterogeneous, I don’t think that one single protein would be able to help us. What I would foresee as an individual approaches us, that we might do a panel. There’s a series of questions that has to be asked. The immune process itself is sequential and acts, I think, as a cascade, and we have some biomarkers today that are available. I think you could argue them as biomarkers that help us in decision-making, that help the clinician decide what might be the best therapy, at least in terms of risk-benefit balance, but we just don’t have enough of them to be able to make the kinds of personalized decisions that I think we all hope we’ll be able to make one day.   MSDF Would you mention a couple of the ones that are – or some of the ones – that are available now?   Dr. Dunn So one example that I think would be well agreed on is the presence or absence of JC virus infection that can now be measured by a two-step ELISA assay, with a false-positive rate of an estimated 2.5%. One of the great challenges we face in treating MS is that we have to, in some respects, down-regulate the immune system to protect the brain and central nervous system, but we can’t overshoot the mark to cause a systemic immunosuppression. Immunosuppression can manifest in a number of different ways, including opportunistic infections and even malignancy. One of the most lethal and daunting of the opportunistic infections is a condition called progressive multifocal leukoencephalopathy – that’s precisely why we tend to call that PML instead, three syllables is far preferable – and that condition is caused by an infection of an otherwise relatively benign virus called JC virus, that if it gets into the central nervous system and begins to affect oligodendrocytes and cells of the central nervous system, can cause rapid intracellular proliferation and damage to the brain; that can spread geometrically throughout the brain and can cause very profound brain damage, and sometimes cases of death as well.   We’ve known of PML previously in patients with lymphoma and also in patients with untreated HIV infection who had severe and advancing immunosuppression. But we’ve seen this same PML condition in immunocompetent patients who have been treated with some of the agents that we might use for multiple sclerosis. This concern is not unique to MS, but it’s a concern with any immunotherapy that you use. The ability to measure whether a patient has previously been infected with a JC virus or not helps us in the risk-benefit balance considerations we have to make on behalf of our patients. It’s known that the absence of evidence of a JC virus infection is associated with a markedly decreased risk of PML, whereas its presence means that’s an active consideration in our prescribing.    Now that, I think, functions as a biomarker. Any time you might see an elevation of a measurable protein or another biomarker in general that normalizes with remission that gives you the opportunity to suggest that that either might be a therapeutic target – so let’s just call it protein X, for example, just for simplification and clarification. If a patient having an MS attack has a measurable increase in protein X in their blood which then now returns to normal or what had been their previous baseline in remission, that tells the clinician investigator that protein X might either be part of the immunologic cascade that causes the MS attack, and therefore suggests that the ability to intervene, down-regulate, or modify the expression of protein X may help with disease pathogenesis, OR it could also mean, or it could emerge as a candidate as a tool of assessment for disease status, so that one question we always have to ask as clinicians when we start patient on any given therapy or just in following them is how are they doing. Of course, that’s a primary mandate for the clinician taking care of patients.   Today, we do that by asking how they’re feeling, we strive to get into quality of life metrics with them, we also turn to their examination findings to look for interval change, and we look at MRI to see if there’s been a change there, with the hope that we’re seeing no evidence of disease activity. But the field of multiple sclerosis does not have its own version of a hemoglobin A1c, such as our endocrinologists have. In that scenario for those that aren’t familiar with it, A1c can be a value obtained literally with a single drop of blood that tells the practicing clinician caring for the patient what the average blood sugar of that patient has been over a substantial period of time prior to the time of their clinical encounter. So it helps the clinician make wise judgments and counsel to the patient regarding the optimum way to treat their diabetes, whether adjustments have to be made in their diet or in their prescription medications.   We don’t have such a thing in multiple sclerosis today. If we could find such a thing, it would make our care, I think, far superior in its quality. I think it would make physicians’ advice to our patients far more wise, and it would make the entire medical enterprise of caring for the MS patient less expensive, because we wouldn’t have to resort to important but still somewhat stodgy and expensive technologies like serial MRIs done with what could be high-frequency for the patient. Serial MRIs are safe for the patient, but you can see that if we could identify such a biomarker as that, if that were possible, I think that would have revolutionary implications for our care of the MS patient, not just in reducing medical costs – that’s an important goal – but the more important goal and what physicians need to focus on is superior advice, improved advice and counsel to the patients that are in our care.     MSDF So you and I are both old enough to remember when the Human Genome Project was proposed, and one of the values of the Human Genome Project that was articulated was that it would usher in an era of personalized medicine. Now it’s 13 years or so after the Human Genome Project has been completed, and, arguably, that promise has never been realized. How much longer will it take in multiple sclerosis to realize an era of personalized medicine?   Dr. Dunn The short answer is I don’t know, but there’s some important considerations to be made along the way. One fact is there are approximately 25,000 genes in the human body, but there are an estimated 500,000 proteins. The reason for the difference is that after an original protein is manufactured on the basis of the blueprint of DNA, it can be modified in transcription and translation. For those of you in your field, this would be post-production modifications. The same thing happens with proteins, and what that means is that the field of proteomics, you could argue, is 20 times more sensitive than the field of genomics if the ratio is 25,000 to 500,000 genes to proteins in the human body, respectively.   MS does have a genetic component, and that’s been proven by research in this past two decades by our country’s leading researchers, but the genetic input of MS is not the only answer; MS is only partially a genetic disease. It seems to be, in my own opinion and I think it’s shared by my colleagues – many of them, most of them perhaps – is that MS is primarily an environmental condition. The greatest risk of obtaining MS is not so much that family members are affected, though cases of that have happened and happen regularly, it seems to be more related to environment, where one lives. Now you may know that epidemiologically, MS is almost absent, or very sparse, at the equator, but in moving north and south on Earth, the greater that one moves away from the equator, the greater the prevalence of MS. And right about the 35th parallel or so both north and south of the equator, there appears to be a relatively large increase in how much MS there is. And that’s true, to the best of our knowledge, all the way around the world.   And so if MS is more of an environmental condition than a genetic one – although it’s both – then I think a genetic assay may be part, but not likely to be all of the answer, and the promise of going to a more sensitive assay to get into the post-transcription and post-translational modification that takes place in human molecules, which ultimately are the language of how the immune system affects our nervous system, is going to be and prove to be a more enriched and more promising field of inquiry.   MSDF I wonder if you can mention some of the labs that are doing the most promising work in this area.   Dr. Dunn I’m pleased to say that there are labs throughout the world that I think are doing research in this. Within the United States – I don’t want to leave anybody out – but I think that special kudos need to be given to the Mayo Clinic. I think on the east coast the Partners Program of the Harvard Medical Schools are very interested in this field; Johns Hopkins is doing work that I think is exemplary. Out west, our colleagues at UCSF. And, of course, I have to give special kudos to my colleagues at Stanford University. These are places that are publishing in translational medicine the bench-to-bedside framework in which discoveries that are being made at the level of the bench, there’s an active effort being made to try to translate that to human care. I’m very sensitive to the idea of excluding anybody, because I think that this is really an international search, and it’s going to require multilevel of collaboration. So I hope that as we go forward, we’ll be able to really work together.   I mentioned just a moment ago, I think practice of personalized medicine in this field is going to require not one discovery, it’s going to require a panel, perhaps, of different measurable biomarkers. I don’t anticipate one single lab is going to be able to discover all of those biomarkers, I think we’ll get one discovery from one place, one from another, one from another. And it’s going to require a transcendent collaboration between institutions and individuals and researchers and investigators to bring it all together for the collective good.   MSDF Dr. Dunn, thank you very much.   Dr. Dunn Okay, alright, thank you very much, Bob.   [transition music]   Thank you for listening to Episode Six of Multiple Sclerosis Discovery. This Podcast was produced by the MS Discovery Forum, MSDF, the premier source of independent news and information on MS research. MSDF’s executive editor is Robert Finn. Msdiscovery.org is part of the nonprofit Accelerated Cure Project for Multiple Sclerosis. Robert McBurney is our President and CEO, and Hollie Schmidt is Vice President of Scientific Operations.   Msdiscovery.org aims to focus attention on what is known and not yet known about the causes of MS and related conditions, their pathological mechanisms, and potential ways to intervene. By communicating this information in a way that builds bridges among different disciplines, we hope to open new routes toward significant clinical advances.   We’re interested in your opinions. Please join the discussion on one of our online forums or send comments, criticisms, and suggestions to editor@msdiscovery.org.   [outro music]